18F-FDG PET-CT in the Management of Patients Receiving Definitive Radiotherapy for Malignancies of the Head and Neck
Table 2
Diagnostic performance of serial 18F-FDG PET-CT studies in the identification of residual/recurrent malignancy or second primary cancers following intensity modulated radiation therapy (IMRT) ± combined chemotherapy for treatment of primary cancers of the head and neck.
TP
FP
FN
TN
Sensitivity
Specificity
PPV
NPV
Accuracy
First posttreatment PET-CT (156 ± 125 d., median 122 d.)
153
25 (16.3%)
8 (5.2%)
0 (0%)
120 (78.5%)
100.0%
93.8%
75.8%
100.0%
94.8%
Second posttreatment PET-CT (445 ± 332 d., median 333 d.)
101
19 (18.8%)
3 (3.0%)
0 (0%)
79 (78.2%)
100.0%
96.3%
86.4%
100.0%
97.0%
Third posttreatment PET-CT (551 ± 354 d., median 462 d.)
60
11 (18.3%)
1 (1.7%)
0 (0%)
48 (80%)
100.0%
98.0%
91.7%
100.0%
98.3%
Fourth posttreatment PET-CT (891 ± 415 d., median 846 d.)
